Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Valuing Health at the End of Life: A Review of Stated Preference Studies in the Social Sciences Literature
9 April 2018
Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.

Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?
4 April 2018
A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.

Value Frameworks: Value in Health Special Issue
29 March 2018
A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the…

Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?
22 March 2018
A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.

OHE Lunchtime Seminar: Valuing Children’s Health for Economic Evaluation
15 February 2018
OHE Lunchtime Seminar with Oliver Rivero-Arias on Valuing Children’s Health for Economic Evaluation. 29 March 2018 12:00-2:00pm

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
1 August 2018
This OHE Research paper by Karla Hernandez-Villafuerte, (German Cancer Research Center, DKFZ), Bernarda Zamora (OHE) and Adrian Towse (OHE) sets out a research agenda proposing new…

A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018)…

OHE at HESG Winter 2018
4 January 2018
A summary of OHE’s activity at the 2018 winter HESG meeting, City, University of London, 10-12th January.

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
1 March 2018
The report addresses the implications of NICE appraising treatments for very rare diseases using a cost-per-QALY gained decision rule of the type used by NICE in…